This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Vansen Pharma Inc.
Drug Names(s): cefditoren pivoxil
Description: Spectracef is a semisynthetic, broadspectrum, third-generation cephalosporin indicated for the treatment of mild-to-moderate infections in adults and adolescents. As with other cephalosporins, Spectracef inhibits bacterial cell wall synthesis by binding penicllin binding proteins. It exhibits good activity against streptococci, and enteric Gram-(-) rods; moderate activity against methicillin-sensitive strains of Staphylococcus aureus; and poor activity against enterococci, Pseudomonas, anaerobes, and MRSA.
Vansen, which acquired Spectracef in March 2012, does not report sales for Spectracef.
Meiji and Purdue
Spectracef, an oral antibiotic, was approved by the FDA in 2001 and was relaunched in 2003 by Purdue Pharmaceutical Products under an exclusive licensing agreement with Meiji Seika Kaisha Ltd of Japan.
In a Settlement Agreement dated March 2006, it was agreed that the Purdue License Agreement will terminate effective upon the earlier to occur of the date on which Meiji Seika Kaisha and a new partner introduced by Purdue enter into a license agreement with respect to the product containing Cefditoren Pivoxil in the United States or October 31, 2006.
Cornerstone and Meiji
In October 2006, Cornerstone (CBI) and Meiji entered into a license and supply agreement granting CBI an exclusive, nonassignable U.S. license to manufacture and sell Spectracef, using cefditoren pivoxil supplied by Meiji, for its currently approved therapeutic indications...See full deal structure in Biomedtracker
Partners: Meiji Seika Pharma Co., Ltd
Pink Sheet TAP Spectracef supplemental indication
Additional information available to subscribers only: